Activity
(Activity: Sample activity data. For lot-specific information, please refer to the specific datasheet.)
COVID 19 Spike S1 (delta69-70 delta144 N501Y A570D D614G P681H) Coronavirus Recombinant Protein | COVID-19 recombinant protein
2019-nCoV Spike protein S1 (delta69-70 delta144 N501Y A570D D614G P681H)
Synonyms
COVID 19 Spike S1 (delta69-70 delta144 N501Y A570D D614G P681H) Coronavirus; 2019-nCoV Spike protein S1 (delta69-70 delta144 N501Y A570D D614G P681H); 2019 Novel Coronavirus; Coronavirus; CoV; COVID-19 virus; HCoV-2; Human Coronavirus 2019; SARS2; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Spike S1 (delta69-70 delta144 N501Y A570D D614G P681H); 2019-nCoV s1; SARS-CoV-2 spike S1; SARS-CoV-2 S1; novel coronavirus spike s1; nCov spike s1; coronavirus spike S1.; COVID-19 recombinant protein
Host
CHO cells
Form/Format
Recombinant protein stored in 50mM sodium phosphate, pH7.5, 300mM NaCl, 150mM imidazole.
Concentration
0.5ug/ul (determined by densitometry) (varies by lot)
Tag
HIS
Species
SARS-CoV-2
Preparation and Storage
Store product at -70 degree C. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.
Activity
(Activity: Sample activity data. For lot-specific information, please refer to the specific datasheet.)
Activity
(Activity: Sample activity data. For lot-specific information, please refer to the specific datasheet.)
SDS-Page
(Purity: Sample purity data. For lot-specific data, please refer to the respective datasheet.)
SDS-Page
(Purity: Sample purity data. For lot-specific data, please refer to the respective datasheet.)
Related Product Information for COVID-19 recombinant protein
Recombinant 2019-nCoV Spike protein S1 (delta69 -70 delta144 N501Y A570D D614G P681H)(16-685) was expressed in CHO cells using a C-terminal His-tag. The gene accession number is MN908947.
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) remains the most rapidly spreading disease since 2020. The spike glycoprotein (S) of coronavirus, a type I transmembrane protein containing two subunits S1 and S2, facilitates viral genome entry into the host cells through the interaction with angiotensin-converting enzyme 2 (ACE2)(1). The current UK variant B.1.1.7 contains 9 out of 23 mutations in the Spike protein. Of the mutations found in the Spike protein of the UK variant, delta69-70 and D614G have been associated with higher viral infectivity. N501Y is known to increase affinity for ACE2 and P681H mutation found adjacent to the furin cleavage site possibly plays a role in spike protein processing (2,3).
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) remains the most rapidly spreading disease since 2020. The spike glycoprotein (S) of coronavirus, a type I transmembrane protein containing two subunits S1 and S2, facilitates viral genome entry into the host cells through the interaction with angiotensin-converting enzyme 2 (ACE2)(1). The current UK variant B.1.1.7 contains 9 out of 23 mutations in the Spike protein. Of the mutations found in the Spike protein of the UK variant, delta69-70 and D614G have been associated with higher viral infectivity. N501Y is known to increase affinity for ACE2 and P681H mutation found adjacent to the furin cleavage site possibly plays a role in spike protein processing (2,3).
Product Categories/Family for COVID-19 recombinant protein
References
1. Lan J, et al: Crystal structure of the 2019-nCov spike receptor-binding domain bound with the ACE2 receptor. Nature. 2020, 581:215-220.
2. Tada T, et al: Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies. https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1.
3. Korber B, et al: Tracking changes in SARS-CoV-2 Spike: Evidence that D614G increases infectivity of the covid-19 virus. Cell. 2020, 182:812-82.
2. Tada T, et al: Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies. https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1.
3. Korber B, et al: Tracking changes in SARS-CoV-2 Spike: Evidence that D614G increases infectivity of the covid-19 virus. Cell. 2020, 182:812-82.
NCBI and Uniprot Product Information
Similar Products
Product Notes
The COVID-19 (Catalog #AAA516690) is a Recombinant Protein produced from CHO cells and is intended for research purposes only. The product is available for immediate purchase. It is sometimes possible for the material contained within the vial of "COVID 19 Spike S1 (delta69-70 delta144 N501Y A570D D614G P681H) Coronavirus, Recombinant Protein" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
